Alicia K. Wooten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alicia K. Wooten has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Anukul Taranath Shenoy
Dept. of Microbiology and Immunology, University of Michigan Medical School
3 shared publications - Emad I. Arafa
Pulmonary Center
3 shared publications - Joseph P. Mizgerd
Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA
3 shared publications - Lee J. Quinton
Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA
3 shared publications - Matthew R. Jones
Division of Pulmonary, Allergy, Sleep and Critical Care (E.C., S.C., I.G., M.P., F.S., J.P.M., A.F., M.R.J.), Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, MA
3 shared publications - Anna C. Belkina
Department of Virology, Immunology and Microbiology, Chobanian and Avedisian School of Medicine, Boston University , Boston, MA
2 shared publications
Latest Publications
- Open Access
- 1 December 2024
- Published by American Astronomical Society
- Vol. 56 (9)
Including Deaf and Signing Audiences in Solar Eclipse Outreach and Astronomy Education
The solar eclipse of April 8, 2024, offered an invaluable opportunity to engage Deaf, Hard-of-Hearing, and Signing communities in astronomical education and outreach. Deaf and Signing individuals are not sufficiently included in astronomical activities: both in public outreach and in the training of professional scientists. The authors of this article, in working to improve Deaf/Signing inclusion in astronomy education and outreach, have carried out a range of activities in a variety of settings: online via Atomic Hands; at the National Technical Institute for the Deaf in Rochester, NY; at Boston University; and at Gallaudet University in Washington, DC. We cast special attention on our activities associated with the 2024 solar eclipse, which collectively reached thousands of Deaf individuals, as well as other recent astronomy education efforts. We comment on how the community of hearing astronomers can better include Deaf/HH/Signing individuals and communities in their activities.
- 1 December 2024
- Published by American Astronomical Society
- Vol. 56 (9)
Open AccessIncluding Deaf and Signing Audiences in Solar Eclipse Outreach and Astronomy Education
The solar eclipse of April 8, 2024, offered an invaluable opportunity to engage Deaf, Hard-of-Hearing, and Signing communities in astronomical education and outreach. Deaf and Signing individuals are not sufficiently included in astronomical activities: both in public outreach and in the training of professional scientists. The authors of this article, in working to improve Deaf/Signing inclusion in astronomy education and outreach, have carried out a range of activities in a variety of settings: online via Atomic Hands; at the National Technical Institute for the Deaf in Rochester, NY; at Boston University; and at Gallaudet University in Washington, DC. We cast special attention on our activities associated with the 2024 solar eclipse, which collectively reached thousands of Deaf individuals, as well as other recent astronomy education efforts. We comment on how the community of hearing astronomers can better include Deaf/HH/Signing individuals and communities in their activities.
- Open Access
- 10 August 2023
- Published by Springer Nature in Nature Reviews Materials
- Vol. 8 (10) , 645-650
Advancing scientific discourse in American Sign Language
- 10 August 2023
- Published by Springer Nature in Nature Reviews Materials
- Vol. 8 (10) , 645-650
Open AccessAdvancing scientific discourse in American Sign Language
- Open Access
- 8 March 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (5)
Recruitment and training of alveolar macrophages after pneumococcal pneumonia
Recovery from pneumococcal pneumonia remodels the pool of alveolar macrophages so that they exhibit new surface marker profiles, transcriptomes, metabolomes, and responses to infection. Mechanisms mediating alveolar macrophage phenotypes after pneumococcal pneumonia have not been delineated. IFN-γ and its receptor on alveolar macrophages were essential for certain, but not all, aspects of the remodeled alveolar macrophage phenotype. IFN-γ was produced by CD4 + T cells plus other cells, and CD4 + cell depletion did not prevent alveolar macrophage remodeling. In mice infected or recovering from pneumococcus, monocytes were recruited to the lungs, and the monocyte-derived macrophages developed characteristics of alveolar macrophages. CCR2 mediated the early monocyte recruitment but was not essential to the development of the remodeled alveolar macrophage phenotype. Lineage tracing demonstrated that recovery from pneumococcal pneumonias converted the pool of alveolar macrophages from being primarily of embryonic origin to being primarily of adult hematopoietic stem cell origin. Alveolar macrophages of either origin demonstrated similar remodeled phenotypes, suggesting that ontogeny did not dictate phenotype. Our data reveal that the remodeled alveolar macrophage phenotype in lungs recovered from pneumococcal pneumonia results from a combination of new recruitment plus training of both the original cells and the new recruits.
- 8 March 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (5)
Open AccessRecruitment and training of alveolar macrophages after pneumococcal pneumonia
Recovery from pneumococcal pneumonia remodels the pool of alveolar macrophages so that they exhibit new surface marker profiles, transcriptomes, metabolomes, and responses to infection. Mechanisms mediating alveolar macrophage phenotypes after pneumococcal pneumonia have not been delineated. IFN-γ and its receptor on alveolar macrophages were essential for certain, but not all, aspects of the remodeled alveolar macrophage phenotype. IFN-γ was produced by CD4 + T cells plus other cells, and CD4 + cell depletion did not prevent alveolar macrophage remodeling. In mice infected or recovering from pneumococcus, monocytes were recruited to the lungs, and the monocyte-derived macrophages developed characteristics of alveolar macrophages. CCR2 mediated the early monocyte recruitment but was not essential to the development of the remodeled alveolar macrophage phenotype. Lineage tracing demonstrated that recovery from pneumococcal pneumonias converted the pool of alveolar macrophages from being primarily of embryonic origin to being primarily of adult hematopoietic stem cell origin. Alveolar macrophages of either origin demonstrated similar remodeled phenotypes, suggesting that ontogeny did not dictate phenotype. Our data reveal that the remodeled alveolar macrophage phenotype in lungs recovered from pneumococcal pneumonia results from a combination of new recruitment plus training of both the original cells and the new recruits.
- Open Access
- 27 February 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (4)
Pneumonia recovery reprograms the alveolar macrophage pool
Community-acquired pneumonia is a widespread disease with significant morbidity and mortality. Alveolar macrophages are tissue-resident lung cells that play a crucial role in innate immunity against bacteria that cause pneumonia. We hypothesized that alveolar macrophages display adaptive characteristics after resolution of bacterial pneumonia. We studied mice 1 to 6 months after self-limiting lung infections with Streptococcus pneumoniae , the most common cause of bacterial pneumonia. Alveolar macrophages, but not other myeloid cells, recovered from the lung showed long-term modifications of their surface marker phenotype. The remodeling of alveolar macrophages was (a) long-lasting (still observed 6 months after infection), (b) regionally localized (observed only in the affected lobe after lobar pneumonia), and (c) associated with macrophage-dependent enhanced protection against another pneumococcal serotype. Metabolomic and transcriptomic profiling revealed that alveolar macrophages of mice that recovered from pneumonia had new baseline activities and altered responses to infection that better resembled those of adult humans. The enhanced lung protection after mild and self-limiting bacterial respiratory infections includes a profound remodeling of the alveolar macrophage pool that is long-lasting; compartmentalized; and manifest across surface receptors, metabolites, and both resting and stimulated transcriptomes.
- 27 February 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (4)
Open AccessPneumonia recovery reprograms the alveolar macrophage pool
Community-acquired pneumonia is a widespread disease with significant morbidity and mortality. Alveolar macrophages are tissue-resident lung cells that play a crucial role in innate immunity against bacteria that cause pneumonia. We hypothesized that alveolar macrophages display adaptive characteristics after resolution of bacterial pneumonia. We studied mice 1 to 6 months after self-limiting lung infections with Streptococcus pneumoniae , the most common cause of bacterial pneumonia. Alveolar macrophages, but not other myeloid cells, recovered from the lung showed long-term modifications of their surface marker phenotype. The remodeling of alveolar macrophages was (a) long-lasting (still observed 6 months after infection), (b) regionally localized (observed only in the affected lobe after lobar pneumonia), and (c) associated with macrophage-dependent enhanced protection against another pneumococcal serotype. Metabolomic and transcriptomic profiling revealed that alveolar macrophages of mice that recovered from pneumonia had new baseline activities and altered responses to infection that better resembled those of adult humans. The enhanced lung protection after mild and self-limiting bacterial respiratory infections includes a profound remodeling of the alveolar macrophage pool that is long-lasting; compartmentalized; and manifest across surface receptors, metabolites, and both resting and stimulated transcriptomes.
- Open Access
- 5 July 2016
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 1-13
miR-155 in the progression of lung fibrosis in systemic sclerosis
MicroRNA (miRNA) control key elements of mRNA stability and likely contribute to the dysregulated lung gene expression observed in systemic sclerosis associated interstitial lung disease (SSc-ILD). We analyzed the miRNA gene expression of tissue and cells from patients with SSc-ILD. A chronic lung fibrotic murine model was used. RNA was isolated from lung tissue of 12 patients with SSc-ILD and 5 controls. High-resolution computed tomography (HRCT) was performed at baseline and 2–3 years after treatment. Lung fibroblasts and peripheral blood mononuclear cells (PBMC) were isolated from healthy controls and patients with SSc-ILD. miRNA and mRNA were analyzed by microarray, quantitative polymerase chain reaction, and/or Nanostring; pathway analysis was performed by DNA Intelligent Analysis (DIANA)-miRPath v2.0 software. Wild-type and miR-155 deficient (miR-155ko) mice were exposed to bleomycin. Lung miRNA microarray data distinguished patients with SSc-ILD from healthy controls with 185 miRNA differentially expressed (q < 0.25). DIANA-miRPath revealed 57 Kyoto Encyclopedia of Genes and Genomes pathways related to the most dysregulated miRNA. miR-155 and miR-143 were strongly correlated with progression of the HRCT score. Lung fibroblasts only mildly expressed miR-155/miR-21 after several stimuli. miR-155 PBMC expression strongly correlated with lung function tests in SSc-ILD. miR-155ko mice developed milder lung fibrosis, survived longer, and weaker lung induction of several genes after bleomycin exposure compared to wild-type mice. miRNA are dysregulated in the lungs and PBMC of patients with SSc-ILD. Based on mRNA-miRNA interaction analysis and pathway tools, miRNA may play a role in the progression of the disease. Our findings suggest that targeting miR-155 might provide a novel therapeutic strategy for SSc-ILD.
- 5 July 2016
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 18 (1) , 1-13
Open AccessmiR-155 in the progression of lung fibrosis in systemic sclerosis
MicroRNA (miRNA) control key elements of mRNA stability and likely contribute to the dysregulated lung gene expression observed in systemic sclerosis associated interstitial lung disease (SSc-ILD). We analyzed the miRNA gene expression of tissue and cells from patients with SSc-ILD. A chronic lung fibrotic murine model was used. RNA was isolated from lung tissue of 12 patients with SSc-ILD and 5 controls. High-resolution computed tomography (HRCT) was performed at baseline and 2–3 years after treatment. Lung fibroblasts and peripheral blood mononuclear cells (PBMC) were isolated from healthy controls and patients with SSc-ILD. miRNA and mRNA were analyzed by microarray, quantitative polymerase chain reaction, and/or Nanostring; pathway analysis was performed by DNA Intelligent Analysis (DIANA)-miRPath v2.0 software. Wild-type and miR-155 deficient (miR-155ko) mice were exposed to bleomycin. Lung miRNA microarray data distinguished patients with SSc-ILD from healthy controls with 185 miRNA differentially expressed (q < 0.25). DIANA-miRPath revealed 57 Kyoto Encyclopedia of Genes and Genomes pathways related to the most dysregulated miRNA. miR-155 and miR-143 were strongly correlated with progression of the HRCT score. Lung fibroblasts only mildly expressed miR-155/miR-21 after several stimuli. miR-155 PBMC expression strongly correlated with lung function tests in SSc-ILD. miR-155ko mice developed milder lung fibrosis, survived longer, and weaker lung induction of several genes after bleomycin exposure compared to wild-type mice. miRNA are dysregulated in the lungs and PBMC of patients with SSc-ILD. Based on mRNA-miRNA interaction analysis and pathway tools, miRNA may play a role in the progression of the disease. Our findings suggest that targeting miR-155 might provide a novel therapeutic strategy for SSc-ILD.